BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35874074)

  • 1. Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer.
    Kapeleris J; Müller Bark J; Ranjit S; Irwin D; Hartel G; Warkiani ME; Leo P; O'Leary C; Ladwa R; O'Byrne K; Hughes BGM; Punyadeera C
    Heliyon; 2022 Jul; 8(7):e09971. PubMed ID: 35874074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the prognostic role and biological characteristics of circulating tumor cell-associated white blood cell clusters in non-small cell lung cancer.
    Li Z; Fan L; Wu Y; Niu Y; Zhang X; Wang B; Yao Y; Chen C; Qi N; Wang DD; Lin PP; Tang D; Gao W
    J Thorac Dis; 2022 May; 14(5):1544-1555. PubMed ID: 35693614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer.
    Wang Y; Liu Y; Zhang Z; Lu B; Gao Y; Tong L; Hu M; Lin PP; Li B; Zhang T
    BMC Cancer; 2023 Jun; 23(1):578. PubMed ID: 37349714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab.
    Mondelo-Macía P; García-González J; León-Mateos L; Anido U; Aguín S; Abdulkader I; Sánchez-Ares M; Abalo A; Rodríguez-Casanova A; Díaz-Lagares Á; Lago-Lestón RM; Muinelo-Romay L; López-López R; Díaz-Peña R
    Mol Oncol; 2021 Nov; 15(11):2923-2940. PubMed ID: 34465006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
    Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer.
    Markou AN; Londra D; Stergiopoulou D; Vamvakaris I; Potaris K; Pateras IS; Kotsakis A; Georgoulias V; Lianidou E
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer.
    Fernandez-Garcia D; Hills A; Page K; Hastings RK; Toghill B; Goddard KS; Ion C; Ogle O; Boydell AR; Gleason K; Rutherford M; Lim A; Guttery DS; Coombes RC; Shaw JA
    Breast Cancer Res; 2019 Dec; 21(1):149. PubMed ID: 31856868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
    Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer.
    Peng WW; Liu Y; Sha HH; Wen SD; Fang Y; Zhou GR
    BMC Pulm Med; 2023 Sep; 23(1):348. PubMed ID: 37710221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Zhou J; Dong F; Cui F; Xu R; Tang X
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
    Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
    Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer.
    Park CK; Oh HJ; Kim MS; Koh BG; Cho HJ; Kim YC; Yang HJ; Lee JY; Chun SM; Oh IJ
    Transl Lung Cancer Res; 2021 May; 10(5):2103-2117. PubMed ID: 34164263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD47 Expression in Circulating Tumor Cells and Circulating Tumor Microemboli from Non-Small Cell Lung Cancer Patients Is a Poor Prognosis Factor.
    Torres JA; Brito ABC; Silva VSE; Messias IM; Braun AC; Ruano APC; Buim MEC; Carraro DM; Chinen LTD
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer.
    Shishido SN; Carlsson A; Nieva J; Bethel K; Hicks JB; Bazhenova L; Kuhn P
    J Transl Med; 2019 Aug; 17(1):294. PubMed ID: 31462312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of circulating tumour cells (CTCs) and CTC white blood cell clusters in patients with renal cell carcinoma.
    Guan Y; Xu F; Tian J; Gao K; Wan Z; Wang Y; Gao M; Wang Z; Chong T
    BMC Cancer; 2021 Jul; 21(1):826. PubMed ID: 34271857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.
    Davies CR; Guo T; Burke E; Stankiewicz E; Xu L; Mao X; Scandura G; Rajan P; Tipples K; Alifrangis C; Wimalasingham AG; Galazi M; Crusz S; Powles T; Grey A; Oliver T; Kudahetti S; Shaw G; Berney D; Shamash J; Lu YJ
    Front Oncol; 2022; 12():1060864. PubMed ID: 36727071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer.
    Kulasinghe A; Kapeleris J; Kimberley R; Mattarollo SR; Thompson EW; Thiery JP; Kenny L; O'Byrne K; Punyadeera C
    Cancer Med; 2018 Dec; 7(12):5910-5919. PubMed ID: 30565869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
    Bian J; Yan K; Liu N; Xu X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.